Insider Selling: Metacrine, Inc. (NASDAQ:MTCR) Insider Sells 107,054 Shares of Stock
Insider Selling: Metacrine, Inc. (NASDAQ:MTCR) Insider Sells 107,054 Shares of Stock
Metacrine, Inc. (NASDAQ:MTCR – Get Rating) insider Michael York sold 107,054 shares of Metacrine stock in a transaction on Thursday, January 26th. The stock was sold at an average price of $0.41, for a total value of $43,892.14. Following the completion of the transaction, the insider now owns 103,499 shares in the company, valued at $42,434.59. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
梅塔克林公司（NASDAQ：MTCR — 獲得評級）內幕邁克爾·約克於 1 月 26 日（星期四）在一次交易中出售了 107,054 股梅特克林股票。該股票以 0.41 美元的平均價格出售，總價值為 43,892.14 美元。交易完成後，內幕人士現在擁有該公司的 103,499 股，價值為 42,434.59 美元。該銷售在與 SEC 合法提交的文件中披露，可以通過以下方式訪問 此超連結。
Metacrine Price Performance
米塔克林價格表現
Shares of NASDAQ MTCR traded down $0.00 during mid-day trading on Friday, reaching $0.48. The company had a trading volume of 849,659 shares, compared to its average volume of 308,842. The company has a current ratio of 12.15, a quick ratio of 12.15 and a debt-to-equity ratio of 0.34. The stock has a market cap of $20.44 million, a PE ratio of -0.47 and a beta of -0.92. The company has a 50-day moving average price of $0.43 and a two-hundred day moving average price of $0.45. Metacrine, Inc. has a 1-year low of $0.30 and a 1-year high of $0.68.
納斯達克 MTCR 的股票在周五中間交易期間下跌了 0.00 美元，達到 0.48 美元。該公司的交易量為 849,659 股，與其平均交易量為 308,842 股相比。該公司的流動比率為 12.15，快速比率為 12.15，債務與權益比率為 0.34。該股的市值為 20.44 萬美元，私募股票比率為 -0.47，測試值為 -0.92。該公司的 50 天移動平均價為 0.43 美元，200 日移動平均價為 0.45 美元。米特琳有限公司的 1 年低點為 0.30 美元，1 年高點為 0.68 美元。
Metacrine (NASDAQ:MTCR – Get Rating) last issued its earnings results on Monday, November 14th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). On average, equities analysts anticipate that Metacrine, Inc. will post -0.62 earnings per share for the current year.
甲基林（NASDAQ：MTCR-獲取評級）上次發布了其盈利業績，日期為 11 月 14 日（星期一）。該公司報告了該季度每股收益（0.13 美元），缺少分析師的共識估計（0.11 美元）為（0.02 美元）。平均而言，股票分析師預計，Metacrine, Inc. 將在本年度公佈每股盈利 -0.62。
Wall Street Analyst Weigh In
華爾街分析師稱重
Hedge Funds Weigh In On Metacrine
對沖基金對甲基林的權衡
Several large investors have recently made changes to their positions in MTCR. State Street Corp lifted its position in shares of Metacrine by 482.8% during the 2nd quarter. State Street Corp now owns 72,186 shares of the company's stock worth $36,000 after purchasing an additional 59,800 shares during the last quarter. Citadel Advisors LLC lifted its position in shares of Metacrine by 112.5% during the 3rd quarter. Citadel Advisors LLC now owns 136,606 shares of the company's stock worth $66,000 after purchasing an additional 72,306 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Metacrine during the 3rd quarter worth about $84,000. Bank of New York Mellon Corp acquired a new position in shares of Metacrine during the 1st quarter worth about $126,000. Finally, Bank of America Corp DE raised its holdings in Metacrine by 10.5% in the 1st quarter. Bank of America Corp DE now owns 263,340 shares of the company's stock valued at $161,000 after acquiring an additional 24,964 shares in the last quarter. Institutional investors and hedge funds own 34.28% of the company's stock.
一些大型投資者最近對其在 MTCR 的頭寸進行了更改。國街公司在第二季度將其在梅特克林股份的地位提高了 482.8％。在上一季度額外購買 59,800 股股票後，州街公司現在擁有該公司股票的 72,186 股價值 36,000 美元。城堡顧問有限責任公司在第三季度通過 112.5％ 提升了其在 Metacrine 股份的地位。城堡顧問有限責任公司現在擁有該公司股票的 136,606 股，價值 66,000 美元，在上一個季度購買了額外的 72,306 股票後。簡街集團有限責任公司在第三季度收購了 Metacrine 股份的新職位，價值約為 84,000 美元。紐約梅隆銀行在第一季度收購了梅塔克林股份的新頭寸，價值約為 126,000 美元。最後，美國銀行公司 DE 在第一季度將其在梅特克林的持股量增加了 10.5％。美國銀行在上一季度額外收購了 24,964 股後，現在擁有該公司的 263,340 股股票，價值為 161,000 美元。機構投資者和對沖基金擁有該公司股票的 34.28%。
About Metacrine
關於梅塔克林
(Get Rating)
(取得評分)
Metacrine, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc was incorporated in 2014 and is headquartered in San Diego, California.
Metacrine, Inc 是一家臨床階段生物製藥公司，致力於發現和開發針對胃腸疾病患者的療法。它正在開發 MET642，該試驗已完成治療潰瘍性結腸炎的 I 期臨床試驗。梅塔克林公司成立於 2014 年，總部位於加利福尼亞州聖地牙哥。
Featured Stories
特色故事
- Get a free copy of the StockNews.com research report on Metacrine (MTCR)
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- PCE Indicates Slowdown In Spending, Economy Weakens
- 獲取有關二甲基林（MTCR）的研究報告的免費副本
- 為什麼清醒在一天內飆升近 100％
- 乘坐這些鐵路股票以獲得增長和收入
- ASML 今年看到籌碼需求上升，提高了銷售觀點
- KLA 公司：陷入困境的半市場中的實力
- PCE 表明支出放緩，經濟減弱
Receive News & Ratings for Metacrine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metacrine and related companies with MarketBeat.com's FREE daily email newsletter.
接收梅塔克林日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Metacrine 及相關公司的最新新聞和分析師評級的簡要每日摘要。